Albert Bourla, DVM, PhD, Pfizer’s chief executive officer, announced during the company’s third quarter 2019 earnings call that Pfizer has set launch dates for its biosimilar rituximab, Ruxience (referencing Rituxan), and trastuzumab, Trazimera (referencing Herceptin).
Albert Bourla, DVM, PhD, Pfizer’s chief executive officer, announced during the company’s third quarter 2019 earnings call that Pfizer has set launch dates for its biosimilar rituximab, Ruxience (referencing Rituxan), and trastuzumab, Trazimera (referencing Herceptin).
According to Bourla, Ruxience will become commercially available in January 2020, and Trazimera will follow on February 15, 2020. The company previously confirmed that it plans to launch its biosimilar bevacizumab, Zirabev, on December 31, 2019.
Ruxience was approved in July of this year for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis. Trazimera was approved in March of this year for the treatment of HER2-positive breast cancer and metastatic gastric cancer. Zirabev was approved in June of this year for the treatment of metastatic colorectal cancer, non—small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and cervical cancer.
During his comments, Bourla also noted that Pfizer’s efforts to encourage biosimilar-friendly policies and legislation are beginning to bear fruit. “None of our breakthroughs will do any good if patients cannot afford them,” said Bourla, adding that “our proposals regarding biosimilars have been well received,” and bipartisan legislation to promote biosimilars in the United States is advancing.
Bourla indicated that key objectives for Pfizer products in general include reducing patients’ out-of-pocket costs, and aggressively pursing value-based reimbursement that will link reimbursement with outcomes.
In terms of Pfizer’s existing biosimilars business, biosimilar infliximab, Inflectra, which treats inflammatory diseases, saw 8% growth in the United States over 2018, rising from $71 million to $77 million (unaudited). Worldwide, however, sales of the same product, sold as Remsima in other territories, were down by 7%, falling from $166 million in 2018 to $155 million (unaudited).
Biosimilar epoetin alfa, Retacrit, brought in $64 million worldwide, and $42 million in the United States.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.